28499 Investors following Dabur India. Share this News with them.
0
Like this story, share it with millions of investors on M3
Dabur India acquires 72.15% of Fem Care Pharma
Dabur India Ltd today announced the acquisition of 72.15% of Fem Care Pharma Ltd, a leading player in the women's skin care products market, for Rs 203.7 crores in an all-cash deal
Dabur India Ltd today announced the acquisition of 72.15% ofFem Care Pharma Ltd (FCPL), a leading player in the women's skin care products market, for Rs 203.7 Crores in an all-cash deal.
The board of directors of Dabur India Ltd approved the acquisition at a board meeting held in Mumbai today. The transaction ascribes a price per share of Rs 800, which translates into an equity valuation of Rs 282.4 Crores and an enterprise valuation of approximately Rs 300 Crores of Fem Care Pharma Ltd. Dabur will make an open offer for an additional 20% shares in the Company as required under the takeover regulations.
"Acquisition of Fem Care Pharma is in line with our strategy to aggressively expand Dabur's scale of operations and strengthen its presence in the fast moving consumer goods (FMCG) space. This transaction would give Dabur an entry into the high-growth skin care market with an established brand name 'FEM'. Further, Dabur also has the potential to extend the brand into newer and related skin care categories," said Dr. Anand Burman, Chairman, Dabur India Ltd.
Fem Care Pharma Ltd, which has a leadership position in the fairness bleach category and a strong market position in hair removal and liquid soap category, is best known for its brand 'FEM'. The other brands in its portfolio include Oxybleach cream, Botanica anti-ageing cream, Stratum colour protecting hair conditioners, SAKA men's bleach and Bambi fabric softeners. FCPL, which reported a consolidated net profit of Rs 9.75 crores in the first half of the 2008-09 fiscal on a turnover of Rs 54.45 crores, also has a sizeable international market presence in markets such as